Instability in the COPD Diagnosis upon Repeat Testing Vary with the Definition of COPD

Rogelio Perez-Padilla¹ *, Fernando C. Wehrmeister⁴, Maria Montes de Oca³, Maria Victorina Lopez², Jose R. Jardim⁶, Adriana Muino², Gonzalo Valdivia⁵, Julio Pertuze⁵, Ana Maria B. Menezes⁴, PLATINO group³

¹ Sleep Clinic, National Institute of Respiratory Diseases, Mexico City, Mexico, ² Faculty of Medicine, University of the Republic, Montevideo, Uruguay, ³ Pulmonary Division, Hospital Universitario de Caracas, Universidad Central de Venezuela, Caracas, Venezuela, ⁴ Postgraduate program on Epidemiology, Federal University of Pelotas, Pelotas, Brazil, ⁵ Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁶ Federal University of Sao Paulo, Sao Paulo, Brazil

¶ Membership of the Platino group is provided in the Acknowledgments.

* perezpad@unam.mx

Abstract

Background
A low FEV₁/FVC from post-bronchodilator spirometry is required to diagnose COPD. Both the FEV₁ and the FVC can vary over time; therefore, individuals can be given a diagnosis of mild COPD at one visit, but have normal spirometry during the next appointment, even without an intervention.

Methods
We analyzed two population-based surveys of adults with spirometry carried out for the same individuals 5-9 years after their baseline examination. We determined the factors associated with a change in the spirometry interpretation from one exam to the next utilizing different criteria commonly used to diagnose COPD.

Results
The rate of an inconsistent diagnosis of mild COPD was 11.7% using FEV₁/FVC <0.70, 5.9% using FEV₁/FEV₆ <the lower limit of the normal range, LLN and 4.1% using the GOLD stage 2-4 criterion. The most important factor associated with diagnostic inconsistency was the closeness of the ratio to the LLN during the first examination. Inconsistency decreased with a lower FEV₁.

Conclusions
Using FEV₁/FEV₆ <LLN or GOLD stage 2-4 as the criterion for airflow obstruction reduces inconsistencies in the diagnosis of mild COPD. Further improvement could be obtained by...
defining a borderline zone around the LLN (e.g. plus or minus 0.6 SD), or repeating the test in patients with borderline results.

**Introduction**

Population-based prevalence of poorly reversible airflow obstruction (COPD) has been recently estimated for a variety of countries in Latin America [1] and other continents [2] with standardized methods including post-bronchodilator spirometry. In those and other surveys, it has been clear that the several criteria to define airflow obstruction would produce important differences in COPD prevalence, which would be lower with criteria based on FEV₁/FVC or FEV₁/FEV₆ below the 5th percentile (lower limit of normal, LLN), than with the traditional Global Initiative for Obstructive Lung Disease (GOLD) definition (FEV₁/FVC<0.7). The majority of the emphasis has been placed on cross-sectional exams and on the impact of COPD criteria on population prevalence, but consistency of diagnosis is also very important for these persons because false positives label them as having a potentially severe disease and false negatives could lead to denial of useful treatments. Additional complications would derive from inconsistency of diagnosis after serial spirometric tests due to known and expected variations in spirometric results after repeated testing that may change the diagnosis along time[3] adding to systematic changes due to aging, and to worsening or improvements in airflow obstruction. In a population-based survey, COPD prevalence based on FEV₁/FEV₆<LLN showed more consistency than criteria based on FEV₁/FVC as the former has fixed times to determine the numerator and denominator of the ratio, whereas FEV₁/FVC only fixes the time to measure the numerator and variations in the expiratory time change the airflow obstruction prevalence [4].

We hypothesized that there would be instability in the designation of abnormal spirometric results depending on the COPD definition used. Therefore, we conducted this study to determine the frequency of change in the diagnosis in the same subjects studied in two population-based surveys, as well as the correlates for these inconsistencies.

**Methods**

The detailed methods of the PLATINO baseline[5] and follow-up studies [6] are available elsewhere. Between the years 2003 and 2005, population-based surveys were conducted employing standardized methodology in five large Latin-American metropolitan areas: Sao Paulo (Brazil), Mexico City (Mexico), Montevideo (Uruguay), Santiago (Chile), and Caracas (Venezuela). We successfully interviewed 1,000 subjects aged 40 years or older in Sao Paulo, 1,063 in Mexico City, 943 in Montevideo, 1,208 in Santiago, and 1,357 in Caracas. Spirometry testing was performed for 963 (97.9%) subjects in Sao Paulo, 1,000 (98.3%) in Mexico City, 885 (97.1%) in Montevideo, 1,173 (99.8%) in Santiago, and 1,294 (98.4%) in Caracas[1]. The questionnaire is available at the PLATINO website: http://www.platino-alat.org. Ethical approval was obtained from the Institutional Review Boards at all five sites (Instituto Nacional de Enfermedades Respiratorias, Universidad Central de Venezuela, Pontificia Universidad Católica de Chile, Federal University of Pelotas and Federal University of Sao Paulo) for the baseline exam and at the three sites participating in the follow-up exams. All participants signed a written informed consent approved by the Boards.

Spirometry was undertaken in individuals who did not present any exclusion criteria (99% of the sample) using an ultrasonic spirometer (EasyOne; ndd Medical Technologies, Zurich, Switzerland). Spirometry was performed before (pre-BD) and 15 minutes after the
administration of 200 μg of Salbutamol (post-BD) according to the American Thoracic Society (ATS) criteria of acceptability and reproducibility [7]. The quality control exercises showed that >90% of the tests fulfilled ATS quality criteria [5].

Follow-up studies were conducted in Montevideo, Santiago, and Sao Paulo 5, 6, and 9 years after the baseline surveys, respectively[6]. Only individuals with valid spirometric data at baseline were eligible for a follow-up exam. Individuals were visited at their homes based on the contact information provided by these during the baseline exam. For the purposes of the present study, only individuals with valid postbronchodilator spirometric tests during both surveys were analyzed.

Data analyses contained the description of the sample characteristics and the calculation of the intraclass correlation coefficient (ICC Rho) between the spirometric parameters (as a continuous variable) in the two tests and the concordance in the diagnosis of COPD (as dichotomic data using the ICC Rho and the Kappa coefficient) with the following criteria: a) LLN [8–10]—defined as the lower 5th percentile for predicted post-BD FEV₁/FVC based on equations derived from the baseline study in a sub-set of healthy and never smoking subjects [11]; b) a ratio of the post-BD FEV₁ over FVC > 0.70 according to the Global Initiative for Obstructive Lung Disease (GOLD)[12,13]; c) FEV₁/FVC₉ < LLN defined as the lower 5th percentile for predicted post-BD FEV₁/FEV₆ based on PLATINO reference equations [11]; d) GOLD stages 2–4 defined as FEV₁/FVC < 0.7 & FEV₁ < 80% predicted, that has been used increasingly to add specificity, and similar indices based on LLN, e.g. FEV₁/FVC & FEV₁ < LLN, and FEV₁/FEV₆ & FEV₁ < LLN.

The probability of an inconsistent spirometric diagnosis during the second examination (one with COPD and the other with no COPD) versus consistent results (both with the same diagnosis) was estimated from logistic regression models, including as independent variables the deviation of the measured FEV₁/FVC and FEV₁/FEV₆ (in standard deviations [SD] from predicted) from the LLN and, in addition, adjustment by several confounders (forced expiratory time, age, gender, current smoking, cumulative smoking in pack-years, the presence of respiratory symptoms, and previous physician diagnosis of respiratory diseases obtained from a questionnaire). Weight and height were measured, and Body mass index (BMI) was categorized into two groups: normal and overweight/obesity. Although in the present work we do not analyze adverse outcomes in detail[14], we investigated if indices giving less inconsistencies on repeated testing also better predicted risk of death and the risk of two or more exacerbations in the previous year. In the presence of airflow obstruction (for the different definitions) we estimated risk of death during follow-up from proportional hazard models (Cox regression done in all individuals including those who died and did not performed the second spirometry) and risk of more than 2 exacerbations in the previous year with a logistic regression model taking into account age and gender. All of the analyses were adjusted for study site (country) and were stratified by gender.

Results

Table 1 describes the main baseline characteristics of the study participants. Follow-up exams were conducted for 885 adults in Montevideo, 1,173 in Santiago, and 963 in Sao Paulo. Information was obtained for 758 (85.6%), 993 (84.7%) and 748 (77.7%) subjects, respectively, of whom 2,026 had a good quality post-BD spirometry test during both examinations (68.8% of those with post bronchodilator testing in the first evaluation and 75.6% of those with post bronchodilator testing in the first evaluation surviving or lost at the time of the second evaluation) (see Table 2). Follow-up rates for each independent variable category were around 80% [5,6]
Compared with the first examination, individuals with a follow-up exam had less current smoking, and with slightly lower lung function. Mean Forced expiratory time (FET) decreased by about 1 second but was >6 seconds on average, and the rate of valid tests decreased from 90% to 83%. The coefficient of variability of FEV1/FEV6 was lower than that of FEV1/FVC, both before and after BD in both examinations.

**Fig. 1** depicts a scatter plot of the FEV1/FVC and **Fig. 2** the FEV1/FEV6 both expressed as Z-scores of the PLATINO predicted values. Dispersion is narrower with FEV1/FEV6 (Intraclass correlation coefficient Rho 0.81, 95%CI 0.78–0.84) when compared to the FEV1/FVC (ICC Rho 0.77, 95%CI 0.74–0.79). Reliability for diagnosis (FEV1/FVC or FEV1/FEV6 as a dichotomic variable) measured similarly by the ICC Rho were much lower numerically than the ICC Rho coefficients for original variables: for GOLD criteria was 0.57 (95%CI 0.54–0.60), for GOLD stages 2–4 was 0.64 (95%CI 0.61.0.66), for FEV1/FEV6<LLN was 0.64 (95%CI 0.61–0.66) and for FEV1/FVC<LLN 0.57 (95%CI 0.61–0.66) (**S1 Table**).

| Table 1. Characteristics of the 2,026 adults who participated in both examinations and had a valid spirometry test. |
|---------------------------------------------------------------|---------------|---------------|---------------|
|                                                      | **First exam** | **Second exam** |
|                                                      | Mean (%)       | SD (or 95%CI)  | Mean (%)       | SD (or 95%CI)  |
| Men (95%CI)                                           | 40.6           | 39.0–42.2     | -             | -             |
| Age (years)                                           | 55.6           | 10.9          | 62.2           | 10.8          |
| Height (cm)                                           | 160.4          | 9.7           | 159.8          | 9.8           |
| BMI (Kg/m²)                                           | 28.3           | 5.7           | 28.8           | 5.3           |
| FEV₁ pre-BD (L)                                       | 2.65           | 0.78          | 2.42           | 0.77          |
| FVC pre-BD (L)                                        | 3.56           | 0.99          | 3.24           | 0.97          |
| FEV₁ post-BD (L)                                      | 2.74           | 0.77          | 2.50           | 0.77          |
| FVC post-BD (L)                                       | 3.54           | 0.96          | 3.26           | 0.96          |
| FEV₁/FVC pre-BD                                       | 74.3           | 8.2           | 74.7           | 8.5           |
| FEV₁/FVC post-BD                                      | 77.7           | 8.1           | 76.8           | 8.5           |
| FEV₁/FEV₆ pre-BD                                      | 78.1           | 6.2           | 77.7           | 6.9           |
| FEV₁/FEV₆ post-BD                                     | 80.4           | 6.2           | 79.2           | 6.8           |
| COV FEV₁/FVC pre-BD                                   | 0.80           | 0.37–1.47     | 0.78           | 0.34–1.44     |
| COV FEV₁/FVC post-BD                                  | 0.67           | 0.30–1.25     | 0.68           | 0.31–1.34     |
| COV FEV₁/FEV₆ pre-BD                                  | 0.47           | 0.23–0.91     | 0.45           | 0.20–0.86     |
| COV FEV₁/FEV₆ post-BD                                 | 0.42           | 0.19–0.76     | 0.45           | 0.20–0.86     |
| Good quality pre-BD* (95%CI)                          | 90             | 89–92         | 83             | 81–85         |
| Good quality post-BD* (95%CI)                         | 91             | 90–93         | 79             | 77–81         |
| FET pre-BD (s)                                        | 11.7           | 3.9           | 9.9            | 3.9           |
| FET post-BD (s)                                       | 10.3           | 3.4           | 9.4            | 3.7           |
| History of Asthma (95%CI)                             | 16.4           | 14.6–18.1     | 16.0           | 14.1–17.1     |
| History of COPD (95%CI)                               | 4.2            | 3.3–5.1       | 6.2            | 5.1–7.3       |
| Current smoker (95%CI)                                | 31.1           | 28.8–33.5     | 25.3           | 23.2–27.4     |

BMI = weight/height²; COV = Coefficient of variability, expressed as medians, 25th and 75th percentiles. SD = Standard deviation; FET = forced expiratory time; pre-BD = before bronchodilator; post-BD = after Bronchodilator. Good quality = three acceptable tests with two best FEV₁ and FVC within <150mL. LLN = lower limit of normal; 95%CI = 95% confidence interval.

doi:10.1371/journal.pone.0121832.t001
Inconsistent diagnoses occurred with all three criteria, but were more common when utilizing the GOLD criterion. Tables 2 and 3 describes the individuals switching spirometric diagnoses in the two examinations according to the airflow obstruction criteria as a proportion those with and without airflow obstruction (Table 2) or as a proportion of the total population (Table 3). Population inconsistencies were highest for GOLD criterion (11.7%), intermediate for FEV1/FVC < LLN (6.5%), and lowest for the FEV1/FEV6 < LLN criterion (5.9%). Prevalence of airflow obstruction and inconsistency in diagnosis was further reduced using indices requiring a low FEV1 in addition to a low ratio: GOLD-2–4 (4.1%), FEV1/FVC & FEV1 < LLN (2.2%) AND FEV1/FEV6 & FEV1 < LLN (2.7%) (See Table 3). In Table 3 also note that in general indicators giving the lowest inconsistency in longitudinal diagnosis also provided the lowest population prevalence, the highest hazard ratio for mortality in Cox regression models and the highest risk of having 2 or more exacerbations in the previous year adjusting by age and gender. In addition, in logistic regression models (adjusted by age and gender), individuals with airflow obstruction in both evaluations had increased risk of exacerbations compared to those with inconsistent airflow obstruction regardless of the criterion of airflow obstruction. For example those with FEV1/FVC < LLN in both evaluations had an OR 2.99 (95%CI 1.2–7.3) of having 2 + exacerbations in the previous year, compared to an OR of 1.6 (0.6–4.0) in those obstructed only in one evaluation. However, the association disappeared if FEV1 expressed as percentage of predicted was included in the models. All individuals with FEV1 <50% predicted were in the consistent COPD diagnosis.

Table 2. Population eligible, spirometries done, individuals switching COPD categories and percentage with 2 or more exacerbations according to several definitions of airflow obstruction (COPD).

| Criteria | Number with post BD spirometry at baseline | Dead at follow up | Alive or lost at follow up | Number with post BD spirometry at follow up | Number switching COPD categories (%) | Percentage with 2 + exacerbations in previous year at 2nd evaluation (95%CI) |
|----------|------------------------------------------|-------------------|--------------------------|------------------------------------------|------------------------------------|------------------------------------------------------------------|
| FEV1/FVC<0.7 (GOLD) | 502 | 96 (19.1) | 406 (80.9) | 300 (73.9) | 91 (30.3) | 2.4 (1.3–4.2) |
| Remaining | 2440 | 169 (6.9) | 2271 (93.1) | 1726 (76.0) | 146 (8.5) | 2.1 (1.6–2.8) |
| FEV1/FVC<LLN | 274 | 50 (18.2) | 224 (81.8) | 167 (74.6) | 68 (40.7) | 2.9 (1.5–5.7) |
| Remaining | 2668 | 215 (8.1) | 2453 (91.9) | 1859 (75.8) | 63 (3.4) | 2.1 (1.6–2.7) |
| FEV1/FEV6<LLN | 251 | 48 (19.1) | 203 (80.9) | 149 (73.4) | 45 (30.2) | 3.6 (1.9–6.8) |
| Remaining | 2691 | 217 (8.1) | 2474 (91.9) | 1877 (75.9) | 86 (4.6) | 2.0 (1.6–2.7) |
| GOLD 2–4 | 191 | 47 (24.6) | 144 (75.4) | 110 (76.4) | 29 (26.4) | 4.2 (2.1–8.2) |
| Remaining | 2751 | 218 (7.9) | 2533 (92.1) | 1916 (75.6) | 54 (2.8) | 2.0 (1.6–2.6) |
| FEV1/FVC & FEV1<LLN | 101 | 25 (24.6) | 76 (75.2) | 58 (76.3) | 21 (36) | 7.9 (4.0–15.1) |
| Remaining | 2841 | 240 (8.4) | 2601 (91.6) | 1968 (69.3) | 23 (1.2) | 2.0 (1.5–2.6) |
| FEV1/FEV6 & FEV1<LLN | 106 | 25 (23.6) | 81 (76.4) | 61 (75.3) | 20 (32.8) | 7.5 (3.8–14.4) |
| Remaining | 2836 | 240 (8.5) | 2596 (91.5) | 1965 (69.3) | 34 (1.7) | 2.0 (1.5–2.6) |

PostBD = post bronchodilator; Switched categories includes the number and the percentage with reference to previous column spirometry at follow up. 2026 subjects with two spirometries; GOLD 2–4 = FEV1/FVC<0.7 & FEV1<80% predicted; LLN = lower limit of normal, the 5th percentile adjusted for gender, age and height. 95%CI = 95% confidence interval.

doi:10.1371/journal.pone.0121832.t002
If inconsistency were expressed as percentage of airflow obstruction prevalence at first evaluation (Table 2 and column 6/column 2 from Table 3), differences among indices would be minor. In addition although prevalence of airflow obstruction may be similar in both evaluations, "abnormal" individuals are not necessarily the same: some of them had a "new diagnosis" at the second evaluation and some "normalized" (see Table 2). For example, from the total of individuals with COPD diagnosis at first examination (see Table 2), 30% would be reverted at second evaluation if using GOLD criteria, 26% if using GOLD stages 2–4, and 33% if using FEV₁/FEV₆ & FEV₁ < LLN.

A new diagnosis of COPD was observed in 7.3% (GOLD), 3.2% (FEV₁/FVC < LLN) and 4.4% (FEV₁/FEV₆ < LLN) of the studied population, whereas a reversed diagnosis of COPD was observed in 4.4% (GOLD), 3.3% (FEV₁/FVC < LLN), and 1.8% (FEV₁/FEV₆ < LLN). Variations of both the numerator and the denominator (FEV₁/FVC or FEV₁/FEV₆) could explain that of the ratios and therefore the diagnosis of airflow obstruction. The majority of individuals with new airflow diagnosis had a drop of FEV₁ in the second evaluation (from 68–82% depending on the criteria) and a minority an increase in FVC or FEV₆ (18 to 34%). In the individuals whose airflow obstruction normalized in the second evaluation this was due (70–94%) to a decrease in FVC or FEV₆ (the denominator) whereas an increase in FEV₁ was observed less frequently (17–48%).

Fig 1. Post-Bronchodilator (BD) FEV₁/FVC in the first vs. the second examination, both expressed as Z-score of the PLATINO predicted values. Lines at -1.645 represent the 5th percentile of the measurement (LLN). Compare with Fig. 2, and observe that dispersion is worse for FEV₁/FVC (Rho concordance 0.74) than for FEV₁/FEV₆ (Rho concordance 0.82).

doi:10.1371/journal.pone.0121832.g001
A decrease in FEV₁ was associated with an increase in BMI, continuous smoking, and use of bronchodilators or corticosteroids whereas an increase in FVC or FEV₆ was associated with a decrease in BMI or lack of use or bronchodilators or corticosteroids but predicting variables explained less than 3% of the variation of the change in FVC, FEV₆ or FEV₁. Therefore >97% of changes in FEV₁, FVC or FEV₆ were unaccounted for by the collected variables. Incident airflow obstruction was associated consistently with age and continuous smoking regardless of the definition but elimination of airflow obstruction was also associated with increased age. Again the variability of the change in spirometric measurements explained by the models was <3%.

If a borderline "buffer zone" is constructed 0.6 SD above and below the LLN of FEV₁/FEV₆, this would include 68% of measurements during the first examination and 63% of the measurements during the second examination. None of the individuals would have changed from no COPD in the first examination to COPD in the second examination (performed 5–9 years later), and only four individuals would have changed from COPD in the first exam to no COPD during the second exam. Therefore, nearly all of the changes in diagnosis would fall within the borderline zone. In addition, in this large borderline zone, only 7/1383 individuals (0.5%) had an FEV₁ <80% predicted (GOLD stage 2) and none had an FEV₁ <50% predicted (GOLD stages 3 or 4). The obstructed category was 16% of the total, and included all GOLD stage 3–4 individuals whereas the normal category was also 16% of the total. The borderline zone could be constructed...
of different sizes, balancing the proportion of false COPD positives and the proportion of individuals with borderline results.

In the logistic regression model (Table 4), inconsistency was associated very powerfully with absolute distance of FEV₁/FVC or FEV₁/FEV₆ (expressed as Z-scores) from the LLN. That is, the closer the measured FEV₁/FVC or FEV₁/FEV₆ to the LLN, the higher the probability of an inconsistent diagnosis during the second examination. For example, the Odds ratio (OR) for an inconsistent diagnosis was 12 (95%CI 8–18) for FEV₁/FVC < LLN, 28 (95%CI 18–45) for FEV₁/FEV₆ < LLN and 7 (95%CI 5–9) for GOLD criterion if the first result was < 0.6 SD (above or below) from the LLN, compared to the remaining participants. Also, the lower the FEV₁, the lower the inconsistency (OR 0.65–0.68 per SD from normality, see Table 5 and Fig. 3).

Table 3. Prevalences of airflow obstruction, frequency of inconsistent longitudinal diagnosis and hazard ratio depending on the definition.

| Criteria | COPD 1 95%CI | COPD 2 95%CI | Inconsistency (%) | 95%CI | Hazard ratio* 95%CI | EXACERBATIONS (OR) 95%CI |
|----------|-------------|-------------|------------------|-------|---------------------|------------------------|
| FEV₁/FVC <0.7 (GOLD) | 14.8 13.2–16.4 | 17.5 15.9–19.2 | 11.7 10.3–13.1 | 1.77 1.3–2.4 | 1.9 0.9–3.9 |
| FEV₁/FVC < LLN | 8.2 7.0–9.4 | 8.0 6.8–9.2 | 6.5 5.4–7.5 | 1.53 1.1–2.2 | 1.9 0.8–3.9 |
| FEV₁/FEV₆ < LLN | 7.4 6.2–8.5 | 10.2 8.9–11.5 | 5.9 4.8–6.9 | 1.70 1.2–2.4 | 2.5 1.1–5.0 |
| GOLD 2–4 | 5.4 4.4–6.4 | 6.6 5.5–7.7 | 4.1 3.2–5.0 | 2.49 1.8–3.5 | 3.1 1.4–7.2 |
| FEV₁/FVC & FEV₁<LLN | 2.8 2.0–3.5 | 3.5 2.7–4.3 | 2.2 1.5–2.8 | 3.06 1.9–4.9 | 5.4 2.4–13.1 |
| FEV₁/FEV₆ & FEV₁<LLN | 3.0 2.2–3.7 | 4.1 3.2–4.9 | 2.7 2.0–3.4 | 2.92 1.8–4.6 | 5.2 2.2–12.1 |

COPD 1 and COPD 2 = sample prevalence (as percentage) of COPD in the first and second evaluation in the 2026 subjects with two spirometries; GOLD 2–4 = FEV₁/FVC<0.7 & FEV₁<80% predicted; LLN = lower limit of normal, the 5th percentile adjusted for gender, age and height. Hazard ratio = the risk of death (n = 2348) from a Cox model adjusting by age and gender based on the presence of airflow obstruction depending on the definition used. Inconsistency is the percentage of participants with a change in diagnosis of airflow obstruction (either a new diagnosis in the second evaluation or the presence of airflow obstruction in the first evaluation but not in the second). Exacerbations = odds ratio of having 2 or more exacerbations in the previous year assessed at the second evaluation in a model adjusted by age and gender. 95%CI = 95% confidence interval.

doi:10.1371/journal.pone.0121832.t003

Table 4. Predicting inconsistency in airflow obstruction diagnosis by a logistic regression model.

| Distance of FEV₁/FVC or FEV₁/FEV₆ from the LLN (standard deviations) | Inconsistency in FEV₁/FVC<LLN | Inconsistency in FEV₁/FEV₆<LLN |
|------------------------------------------------|-------------------------------|-------------------------------|
| Odds Ratio | 95% CI | P        | Odds Ratio | 95% CI | P        |
| 2–3 | 7.8 0.9–6.4 0.06 | 0.9 0.2–4.8 0.9 |
| 1<2 | 9.6 1.2–7.6 0.03 | 2.8 0.6–13 0.17 |
| 0.6<1 | 39.1 5–312 <0.0000 | 8.5 1.9–38 0.005 |
| <0.6 | 108 14–842 <0.00001 | 75.8 18–319 <0.00001 |
| FEV₁ post BD as score Z | 0.68 0.55–0.85 <0.00001 | 0.75 0.60–0.96 0.02 |
| FET (s) first evaluation | 1.2 1.1–1.3 0.001 | 1.06 1.0–1.13 0.04 |
| FET (s) second evaluation | 1.1 1.03–1.1 <0.00001 | 1.02 0.97–1.07 0.45 |
| Pseudo R² | 0.33 | 0.38 |

LLN = lower limit of normal, 5th percentile of the ratio. FET = forced expiratory time; Model was also adjusted by age, gender, asthma, current smoking at second evaluation, a physician diagnosis of asthma. PostBD = post bronchodilator. The closer the ratio and the FEV₁ to the diagnostic threshold, the higher the risk of inconsistency on repeated testing.

doi:10.1371/journal.pone.0121832.t004
Table 5. Inconsistencies in the COPD diagnosis (post bronchodilator spirometry) and some of the predisposing factors. Same participants in two surveys 5–9 years apart.

| Category | Percentage | 95%CI |
|----------|------------|-------|
| **FEV1/FVC < 0.70 (GOLD) INCONSISTENT** |           |       |
| New GOLD | 7.3        | 6.0–8.5 |
| Drop in FEV1 | 67.8     | 60–75  |
| Continue smoking | 27.4    | 20–35  |
| Increase in FVC | 53.4    | 45–62  |
| Use of inhaled medications | 9.6     | 5–14   |
| Physician diagnosed asthma | 8.0    | 5–11   |
| Reversed GOLD | 4.4     | 3.5–5.3 |
| Increase in FEV1 | 25.3    | 16–34  |
| Use of inhaled medications | 7.8     | 2–13   |
| Quit smoking | 29.1    | 10–49  |
| Drop in FVC | 94.5      | 90–99  |
| Increase in weight | 74.7    | 66–84  |
| Physician diagnosed asthma | 5.6    | 4–9    |
| **FEV1/FEV6 < LLN INCONSISTENT** |           |       |
| New FEV1/FEV6 < LLN | 4.4     | 3.4–5.2 |
| Drop in FEV1 | 81.9     | 72–92  |
| Continue smoking | 40.0    | 27–53  |
| Increase in FVC | 34.4    | 22–47  |
| Use of inhaled medications | 13.1    | 4–21   |
| Physician diagnosed asthma | 7.1    | 5–10   |
| Reversed FEV1/FEV6 < LLN | 1.8     | 1.2–2.4 |
| Increase in FEV1 | 19.4    | 6–33   |
| Use of inhaled medications | 16.6    | 4–29   |
| Quit smoking | 25.0     | 1–63   |
| Drop in FVC | 91.7      | 82–100 |
| Increase in weight | 66.6    | 50–82  |
| Physician diagnosed asthma | 3.5    | 2–6    |
| **FEV1/FVC<LLN INCONSISTENT** |           |       |
| New FEV1/FVC<LLN | 3.2     | 2.2–4.0 |
| Drop in FEV1 | 69.8     | 58–81  |
| Continue smoking | 32.3    | 20–44  |
| Increase in FVC | 63.4    | 51–76  |
| Use of inhaled medications | 11.1    | 3–19   |
| Physician diagnosed asthma | 4.4    | 2.7–7.2 |
| Reversed FEV1/FVC<LLN | 3.3     | 2.5–4.1 |
| Increase in FEV1 | 17.6    | 8–27   |
| Use of inhaled medications | 13.2    | 5–21   |
| Quit smoking | 31        | 11–53  |
| Drop in FVC | 94.1      | 88–99  |
| Increase in weight | 72.1    | 61–83  |
| Physician diagnosed asthma | 5.6    | 4–9    |

Percentages on the left part of columns are from the total studied population, whereas those on the right are strata (overlapping) from the above categories. 95%CI = 95% confidence interval; Inconsistent = different result between the two examinations. New GOLD = fulfilling FEV1/FVC<0.70 only during the second exam (similar for the other airflow obstruction criteria). Reversed GOLD = met GOLD criterion during the first examination, but not during the second examination; LLN = lower limit of normal. 

doi:10.1371/journal.pone.0121832.t005
A longer forced expiratory time was also associated with inconsistent diagnosis (OR 1.06–1.22), and a history of wheezing or asthma in some models, but usually with a borderline statistical significance. Other variables analyzed were age, continuous smoking, BMI, gender, clinical diagnosis of COPD, use of respiratory medications and the duration of the expiratory maneuvers, but all together they explained about 7–17% of the variability of inconsistent diagnosis, and the statistical significance disappeared (except for forced expiratory time) once we included in the models the proximity of the spirometry measurements to the threshold for airflow obstruction and FEV₁. The closeness of FEV₁/FVC or FEV₁/FEV₆ to the LLN was the main predictor of switching diagnosis in the two evaluations whether it was a new airflow obstruction in the second evaluation or an airflow obstruction found in the first evaluation disappearing in the second (see S2 Table with information for FEV₁/FEV₆).

**Discussion**

We have described the rates and correlates of inconsistent interpretations of airway obstruction in adults during population-based follow-up examinations according to several criteria of airflow obstruction. There were three important findings. Firstly, the inconsistency of COPD diagnosis was observed with all criteria because these are based on sharp cut-off points (the LLN or a FEV₁/FVC<0.7 for the GOLD criteria plus FEV₁<80% of predicted for GOLD stage 2–4 or FEV₁<LLN): that is, we arbitrarily dichotomize a continuous variable (FEV₁/FVC, FEV₁/FEV₆ for COPD or FEV₁ for GOLD stages). Utilizing the GOLD criterion, an individual with
an FEV₁/FVC of 0.69 would be diagnosed with COPD, and during a follow-up exam, if the ratio were 0.7, the subject would no longer be diagnosed as having COPD. Intraclass correlation coefficient, a measure of concordance was lower numerically for COPD diagnosis than for FEV₁/FVC or FEV₁/FEV₆ as continuous variables. The same problem exists with strict cut-off values based on LLN. Although certain inconsistency is expected, the recommended diagnosis of COPD assumes a single spirometry and therefore does not consider longitudinal inconsistency.

Secondly, airflow obstruction criteria leading to lower population prevalence also produce less inconsistency on repeated testing: the FEV₁/FVC had less concordance in the two tests than FEV₁/FEV₆ whereas the consistency of COPD diagnosis was highest for FEV₁/FEV₆ < LLN and for definitions of airflow obstruction requiring a low FEV₁ (GOLD stage 2–4).

Thirdly, the closeness of the FEV₁/FVC, FEV₁/FEV₆ and FEV₁ to the thresholds or cut points, the higher the possibility of a change in diagnosis on repeated testing (Table 5) independently if the switch represents a new airflow obstruction or a "reversed" airflow obstruction (S2 Table).

Previous studies have shown that the within-test reproducibility of FEV₁/FEV₆ based on 6-second maneuvers was smaller when compared with the traditional FEV₁/FVC [9]. We previously reported that utilizing FEV₁/FEV₆ < LLN provided even more consistent estimates of COPD prevalence in the same populations as criteria based on FEV₁/FVC (GOLD or < LLN). Therefore, we expected that at the individual level, using the 6-second maneuvers would also provide a consistent diagnostic performance from our baseline examination to a follow-up examination; however, the inconsistency rate was not reduced to zero. This may be reduced by adding an interpretation category of "borderline" COPD in other words, by creating a buffer zone immediately around the LLN, as suggested previously by the National Lung Health Education Program (NLHEP) in the United States [15]. This zone would reduce or avoid the changes in diagnosis from extreme groups i.e. from COPD to normal, or from normal to COPD, instead forcing the majority of changes to occur from and to the borderline zone. This strategy would increase confidence in spirometric diagnosis and would be relatively easy to implement compared to a more sound approach of keeping as continuous FEV₁/FVC, FEV₁/FEV₆ and FEV₁ and estimating risks of disease or adverse outcomes or likelihood of response to treatments.

Clinicians usually possess information on individual patients that is not available to Epidemiologists and therefore can use this information to estimate the pre-test disease probability. They can then consider the magnitude of the abnormality from the spirometry test results in order to estimate the post-test probability of COPD. They can also order follow-up tests that will further increase or decrease the probability of COPD, such as a Diffusing capacity (DLCO) test, an exhaled nitric oxide test, induced sputum for eosinophil counts, or a lung Computed tomography scan (looking for emphysema). Clinicians can also perform an asthma therapy trial to determine whether the patient responds, rendering asthma much more likely than COPD. Clinical practice guidelines for hypertension recommend that prior to prescribing blood pressure medication, 3–6 repeated measurements of blood pressure over weeks to months be performed [16]. Perhaps a similar conservative approach should be taken with spirometry for COPD, especially if the results fall within the borderline zone. For these borderline cases, a conservative approach seems adequate because a false COPD label entails costs and potential adverse effects for the patient, including unwarranted bronchodilator prescription or further expensive tests. On the other hand, missing a case of mild COPD has little consequence, as all smokers should be advised to quit smoking regardless of spirometric results, and the majority of drug treatments are meant for moderate or severe COPD.

The main strengths of this study include the population-based sampling, high quality of the spirometry tests (15), the measurement of post-BD spirometry during both examinations and...
the relatively high rates of follow-up after 6–9 years. Limitations of our study include the following: A lack of annual spirometry testing, which could have determined whether or not study participants were “rapid decliners” consistent with COPD progression [15]. Shifts from airway obstruction to normal spirometry during the 5–9 year period could have occurred due to factors that we did not measure, such as respiratory infections or exposure to irritants during the first examinations (but not during the second examination), smoking cessation, or treatment for asthma, COPD, or heart failure; or reductions in exposures causing bronchospasm at the time of the first examination. However, an inconsistent airflow obstruction diagnosis, with any definition was associated significantly with the proximity to the limit of normality and the expiratory time of the tests and therefore likely mostly determined by intrinsic properties of the tests (reliability) rather than true pathobiological processes. Finally, in the current work we did not analyze in detail adverse outcomes, but thresholds giving less prevalence of airflow obstruction, also give less inconsistencies and are associated to a greater risk of death and of exacerbations.

In conclusion, current criteria for airflow obstruction, even those based on age- and gender-adjusted FEV₁/FVC or FEV₁/FEV₆ < LLN, and those requiring in addition a low FEV₁ produce inconsistencies over time that can cause confusing changes in the COPD diagnosis more likely if tests are around the threshold defining airflow obstruction. Diagnosing airflow obstruction using the 6-second spirometry (FEV₁/FEV₆ < LLN) especially if FEV₁ is also low, reduces these inconsistencies compared with criteria based on FEV₁/FVC < LLN or GOLD criterion. Perhaps the inclusion in the diagnostic scheme of a “gray or borderline” zone around the LLN would minimize changes from disease to health or vice-versa. Finally, clinicians should utilize information about the patient to weigh the consequences of a false-positive versus a false-negative disease label before making clinical decisions.

Supporting Information

S1 Dataset. Dataset in Excel (XLS) format.

S1 Table. Reliability by the intraclass correlation coefficient (ICC) and 95%CI between two spirometry tests (at baseline and follow-up) in the same individuals.

S2 Table. Determinants of new and reversed airflow obstruction diagnosis by a logistic regression model using as criteria FEV₁/FEV₆<LLN.

Acknowledgments

We kindly thank Dr. Paul Enright for his thoughtful comments and suggestions. We thank Asociación Latinoamericana de Tórax (ALAT) for helping in the design of the project and for funding part of the project.

The members of the PLATINO group are: AMB Menezes coordinator, MV Lopez and A Muño principal investigators (PIs) in the follow-up in Montevideo, G Valdivia MD and C Lisboa MD PIs in Santiago, JRB Jardim is the PI in São Paulo, C Talamo and M Montes de Oca are the PIs in the PLATINO baseline study in Caracas. R Pérez-Padilla was the PI in the baseline study in Mexico City and the responsible for the spirometry control for this project. The PLATINO group for this study was also comprised by Francisco Franco-Marina MD, Dolores Moreno MD, Carmen Lisboa Oliver A. Nascimento MD, Mariana R. Gazzotti PhD, Graciane Laender PhD and Beatriz Manzano PhD.
Author Contributions
Conceived and designed the experiments: ABM RPP MMO. Performed the experiments: AM MMO GV JP JRJ. Analyzed the data: RPP ABM FW. Wrote the paper: ABM RPP MMO MVL AM JP JRJ.

References
1. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, et al. (2005) Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 366: 1875–1881. PMID:16310554
2. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. (2007) International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 370: 741–750. PMID: 17765523
3. Reddel HK, Roberts B, Crockett A, Thoonen B, Lucas A, Thamrin C, et al. Lack of consistency over time of airways obstruction in respiratory symptomatic current and ex-smokers in primary care; 2014; San Diego, California.
4. Perez-Padilla R, Wehrmeister FC, Celli BR, Lopez-Varela MV, Montes de Oca M, Muino A, et al. (2013) Reliability of FEV1/FEV6 to diagnose airflow obstruction compared with FEV1/FVC: the PLATINO longitudinal study. PLoS One 8: e67960. doi:10.1371/journal.pone.0067960 PMID: 23936297
5. Menezes AM, Victoria CG, Perez-Padilla R (2004) The Platino project: methodology of a multicenter prevalence survey of chronic obstructive pulmonary disease in major Latin American cities. BMC Med Res Methodol 4: 15. PMID:15202950
6. Menezes AM, Muino A, Lopez-Varela MV, Valdivia G, Lisboa C, Jardim JR, et al. (2014) A population-based cohort study on chronic obstructive pulmonary disease in Latin America: methods and preliminary results. The PLATINO Study Phase II. Arch Bronconeumol 50: 10–17. doi: 10.1016/j.arbres.2013.07.014 PMID: 24332830
7. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 152: 1107–1136. PMID: 7663792
8. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O (2002) Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 20: 1117–1122. PMID: 12449163
9. Perez-Padilla R, Hallal PC, Vazquez-Garcia JC, Muino A, Maquez M, Lopez MV, et al. (2007) Impact of bronchodilator use on the prevalence of COPD in population-based samples. COPD 4: 113–120. PMID: 17530504
10. Vollmer WM, Gislason T, Burney P, Enright PL, Gulsvik A, Kocabas A, et al. (2009) Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J 34: 588–597. doi: 10.1183/09031936.00164608 PMID: 19460786
11. Perez-Padilla R, Valdivia G, Muino A, Lopez MV, Marquez MN, Montes de Oca M, et al. (2006) [Spirometric reference values in 5 large Latin American cities for subjects aged 40 years or over]. Arch Bronconeumol 42: 317–325. PMID: 16945261
12. Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23: 932–946. PMID:15219010
13. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256–1276. PMID: 11316667
14. Menezes AMB, Perez-Padilla R, Wehrmeister FC, Lopez-Varela MV, Adriana Munio, Gonzalo Valdivia, et al. (2014) FEV1 is a better predictor of mortality than FVC: The PLATINO cohort study. PLoS One 9: e109732. doi: 10.1371/journal.pone.0109732 PMID: 25285441
15. Ferguson GT, Enright PL, Buist AS, Higgins MW (2000) Office spirometry for lung health assessment in adults: A consensus statement from the National Lung Health Education Program. Chest 117: 1146–1161. PMID: 10767253
16. Watson RD, Lumb R, Young MA, Stallard TJ, Davies P, Littler WA (1987) Variation in cuff blood pressure in untreated outpatients with mild hypertension—implications for initiating antihypertensive treatment. J Hypertens 5: 207–211. PMID: 3611770